Phase 2 Trial

ALX Oncology Holdings Inc (NASDAQ: ALXO) presented initial clinical data from its ongoing Phase 1 / 2 trial evaluating evorpacept combined with azacitidine for untreated higher-risk or relapsed or refractory myelodysplastic syndrome.  The new results were shared at the 63rd...

Viracta Therapeutics Inc (NASDAQ: VIRX) announced final data from its Phase 1b/2 trial of Nana-val in relapsed/refractory (R/R) EBV+ lymphoma. The data were presented at the 2021 American Society of Hematology (ASH) Annual Meeting. Nana-val was well tolerated and demonstrated...

Harpoon Therapeutics Inc (NASDAQ: HARP) presented a poster with interim data from the ongoing dose-escalation portion of the Phase 1/2 trial for HPN217 in patients with relapsed/refractory multiple myeloma. Data were presented at the American Society for Hematology (ASH) Annual...

Janssen, a unit of Johnson & Johnson (NYSE: JNJ), posted longer-term results from the Phase 1b/2 CARTITUDE-1 study of ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy for relapsed / refractory...

BELLUS Health Inc (NASDAQ: BLU) announced topline data its Phase 2b SOOTHE trial of BLU-5937 in Refractory Chronic Cough. The data showed that the 50 mg and 200 mg BID doses of BLU-5937 achieved statistical significance on the primary endpoint with a 34% placebo-adjusted reduction...

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) revealed initial positive results from a Phase 2/3 trial of intramuscular (IM) administration of Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) in acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL). In Cohort 1c...

Roche Holdings AG's (OTC: RHHBY) mosunetuzumab, a bispecific targeting the CD20 protein on the surface of tumors and the CD3 protein on T cells, posted a 60% complete response rate. The data comes from nearly 100 patients with third-line-or-later follicular lymphoma in Phase 1/2...

Bluebird bio Inc (NASDAQ: BLUE) announced updated results from its Phase 1/2 HGB-206 study of lovotibeglogene autotemcel (lovo-cel; formerly LentiGlobin for SCD, bb1111) gene therapy for sickle cell disease. The updated data included further analyses from its pivotal cohort, HGB-206...

Merus NV (NASDAQ: MRUS) has presented updated data on zenocutuzumab (Zeno) combined with trastuzumab and vinorelbine in HER2 positive/amplified (HER2+) metastatic breast cancer who had progressed on anti-HER2 antibody-drug conjugates. The reported data are from the completed phase 2...

Infinity Pharmaceuticals Inc (NASDAQ: INFI) presented updated data from the ongoing MARIO-3 study during the 2021 San Antonio Breast Cancer Symposium (SABCS).  MARIO-3 Phase 2 trial is evaluating eganelisib in combination with Roche Holdings AG's (OTC: RHHBY)...

Moderna Inc (NASDAQ: MRNA) says that it's on its way to having two mRNA vaccines against different seasonal flu viruses. The Company released the first early data from Phase 1 study of mRNA-1010, announcing that all doses of the shot significantly boosted antibodies in younger...

Roche Holdings AG (OTC: RHHBY) reported follow-up efficacy, safety, and patient-reported outcomes data from the Phase 2 CITYSCAPE trial of tiragolumab plus Tecentriq as an initial treatment for PD-L1-positive metastatic non-small cell lung cancer.  After 2.5 years median follow...

Angion Biomedica Corp (NASDAQ: ANGN) and Vifor Pharma shared results from the Phase 2 GUARD trial of Angion's ANG-3777 in cardiac surgery patients with cardiopulmonary bypass at risk for developing acute kidney injury (CSA-AKI).  The trial did not meet its primary...

Innate Pharma SA's (NASDAQ: IPHA) data from the Phase 2 expansion cohort (cohort 3) evaluating the monalizumab triplet combination shows preliminary activity and an acceptable safety profile with a low discontinuation rate. Cohort 3 is exploring the triplet combination of...

Janssen Pharmaceutical, a unit of Johnson & Johnson (NYSE: JNJ), announced additional vaccine efficacy and safety data from its Phase 2b CYPRESS study of its respiratory syncytial virus (RSV) adult vaccine candidate.  J&J shared top-line findings from the Phase 2b...